Fully Human Antibody / TCR Platforms

BsADC Platform

Bispecific ADCs targeting dual tumor-associated antigens (TAAs) enhance cancer treatment by overcoming drug resistance, improving tumor specificity, boosting internalization for better tumor killing, and ensuring stronger, longer-lasting effects in heterogeneous tumors.

  • 20+
    BsADC Assets
  • 200+
    TAA Antibody Backbones
related resource

on this page

  • Advantages of Biocytogen's BsADC Platform
  • Discovery of Novel BsADCs:
  • Off-the-shelf TAA-targeting Antibodies Available for Flexible Plug & Play

Webinars

View All

    Posters

    View All
      Advantages of Biocytogen's Novel bsADC Platform
      • RenLite-derived common light chain antibodies are easy to assemble into BsAb with low mismatch rate and ideal physiochemical properties.
      • Combined with target gene knockout strategy, RenLite KO mice can generate antibodies with increased diversity, potentially against novel epitopes and with cross-species reactivity.
      • Proprietary linker/payload system BLD1102
      • Rapid generation of high-quality BsAbs/BsADCs for high-throughput in vitro and in vivo screening
      Novel linker/payload system BLD1102 independently developed by Biocytogen

      Briefly, BLD1102 is a new ADC platform developed by Biocytogen independently.

      • BCPT02 is a novel topoisomerase 1 inhibitor with broad-spectrum and potent tumor killing ability.
      • The uniquely designed cleavable linker has excellent hydrophilicity, making ADCs as hydrophilic as monoclonal antibodies, greatly improving ADC's physiochemical properties.
      • BLD1102-ADCs exhibit good stability in plasma and more potent tumor killing compared to vcMMAE.
      • BLD1102 demonstrated good tolerabilities in preclinical non-human primates.
      Biocytogen's RenLite-based BsADC Platform

      BsADC developed from RenLite® mice

      Discovery of Novel BsADCs:

      As part of Biocytogen's Project Integrum, combinations of TAA-targeting antibodies generated from RenLite® mice are subsequently assembled and evaluated in vivo for pharmacologic efficacy, and subjected to in vitro analyses. The company's large animal translational platform will further screen out products with better translational properties:

      Off-the-shelf TAA-targeting Antibodies Available for Flexible Plug & Play
      View More
      20+ BsADC Programs Available for Partnership
      Target(s) Immunization
      • Discovery
      • Hits
        selection         Leads
        selection         Candidate
        selection
      		CMC Nonclinical Phase I Status
      EGFR x MET (DM005)
      		Partnered
      TROP2 x EGFR (DM001)
      		Partnered
      HER3 x MUC1 (DM002)
      		Partnered
      HER2 x TROP2 (YH012)
      		Partnered
      EGFR x MUC1(BSA01)
      		Partnered
      EGFR x HER3
      		Partnered
      B7-H3 x PTK7
      		Partnered
      EGFR x PTK7
      SEZ6 x B7-H3
      DLL3 x B7-H3
      DLL3 x SEZ6
      B7-H3 x MUC1
      CDH6 x FOLR1
      TF(CD142) x NECTIN-4
      TF(CD142) x ITGB6
      CDH3 x ITGB6
      ITGB6 x B7-H3
      MUC1 x TROP2
      FOLR1 x MUC1
      MSLN x FOLR1
      MSLN x MUC1
      B7-H4 x FOLR1
      MET x B7-H3
      LGR5 x EGFR